Physician profile
Hala Koudsi
NPI 1912097775
$9,370.24
in general payments reported to CMS, 2019-2025
32 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $652 · 2021: $610 · 2022: $1,589 · 2023: $1,629 · 2024: $1,563 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,505.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,676.80 | 2021-2025 | Bimzelx, Cimzia, Vimpat |
| Pfizer INC. | $1,442.44 | 2021-2025 | |
| Merz North America, INC. | $612.95 | 2023-2025 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $564.54 | 2019-2023 | Targretin |
| Abbvie INC. | $497.59 | 2020-2025 | |
| Genzyme Corporation | $439.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $374.77 | 2020-2025 | Odomzo, Blu-U |
| Organogenesis INC. | $371.40 | 2023-2025 | Via Matrix, Novachor, Nushield |
| Mayne Pharma Commercial LLC | $371.27 | 2023-2025 | |
| Incyte Corporation | $370.64 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $369.94 | 2020-2024 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $301.29 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $278.42 | 2019-2022 | |
| Leo Pharma INC. | $250.15 | 2019-2024 | Adbry |
| Amgen INC. | $229.53 | 2023-2024 | Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $229.43 | 2021-2025 | Ebglyss, Olumiant |
| Janssen Biotech, INC. | $215.04 | 2022-2025 | Tremfya, Simponi, Stelara |
| Botanix Sb INC | $200.63 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 | |
| Celgene Corporation | $91.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $61.85 | 2024 | Sotyktu |
| Ani Pharmaceuticals, INC. | $54.10 | 2025 | Purified Cortrophin Gel |
| Stemline Therapeutics INC. | $46.55 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.73 | 2024 | |
| Sandoz INC. | $22.34 | 2024 | Hyrimoz |
| Strata Skin Sciences, INC. | $22.18 | 2022 | |
| Smith+Nephew, INC. | $21.02 | 2024 | Grafix Pl |
| Arcutis Biotherapeutics, INC. | $19.71 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.88 | 2020 | |
| Journey Medical Corporation | $13.78 | 2020 | |
| Sebela Pharmaceuticals INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hala Koudsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.